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Abstract
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a type of leukodystrophy characterized by white
matter edema, and it is caused mainly by recessive mutations in MLC1 and GLIALCAM genes. These variants are called MLC1
and MLC2A with both types of patients sharing the same clinical phenotype. In addition, dominant mutations in GLIALCAM
have also been identified in a subtype of MLC patients with a remitting phenotype. This variant has been named MLC2B.
GLIALCAM encodes for an adhesion protein containing two immunoglobulin (Ig) domains and it is needed for MLC1
targeting to astrocyte–astrocyte junctions. Most mutations identified in GLIALCAM abolish GlialCAM targeting to junctions.
However, it is unclear why some mutations behave as recessive or dominant. Here, we used a combination of biochemistry
methods with a new developed anti-GlialCAM nanobody, double-mutants and cysteine cross-links experiments, together
with computer docking, to create a structural model of GlialCAM homo-interactions. Using this model, we suggest that
dominant mutations affect different GlialCAM–GlialCAM interacting surfaces in the first Ig domain, which can occur
between GlialCAM molecules present in the same cell (cis) or present in neighbouring cells (trans). Our results provide a
framework that can be used to understand the molecular basis of pathogenesis of all identified GLIALCAM mutations.
Introduction
Leukodystrophies constitute a large group of genetic disorders
primarily affecting CNS white matter (1). Within these, Mega-
lencephalic leukoencephalopathy with subcortical cysts (MLC)
is characterized by early-onset macrocephaly, epilepsy and cere-
bral white matter edema (2). It can be caused by mutations in two
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different genes: MLC1, which is more frequent (3), and GLIALCAM
(4). Detailed characterization of MLC patients with GLIALCAM
mutations revealed two different phenotypes: MLC2A, caused
by two recessive mutations and which is indistinguishable from
patients containing mutations in MLC1, and MLC2B, caused by
one dominant mutation and which shows a remitting, more
benign MLC phenotype (2,5).
MLC1 is a membrane protein of unknown functions (6),
while GlialCAM is an adhesion molecule that belongs to the
immunoglobulin superfamily (7). GlialCAM works as an oblig-
atory subunit of MLC1, being required for MLC1 endoplasmic
reticulum exit and targeting to astrocyte–astrocyte junctions (8–
10). In addition, GlialCAM is further characterized as an auxiliary
subunit of the ClC-2 chloride channel (11), targeting it to cell–cell
junctions and modifying its functional properties (12).
Mutagenesis studies determined that the extracellular
domain of GlialCAM is required for cell junction targeting, as
well as for mediating interactions with itself or with MLC1 and
ClC-2 (13). Accordingly, all MLC missense mutations in GLIALCAM
have been identified in the extracellular domain (2). Within
this domain, most missense mutations are located in the first
Ig domain (IgV type) and affect GlialCAM localization at cell–
cell junctions, observing the same phenotype for mutations
identified in MLC2A or MLC2B patients (4,14,15). In contrast, the
remaining mutations, which are located in the second Ig domain
(IgC2 type), do not affect GlialCAM localization (14).
In order to understand what was the biochemical basis of
the genetic character of these mutations, co-expression exper-
iments in primary astrocytes were performed (4). These exper-
iments revealed that the co-expression of GlialCAM wild-type
(WT) with GlialCAM containing an MLC2B mutation affected the
targeting of GlialCAM WT. In contrast, no effect was observed
in GlialCAM WT upon co-expression with GlialCAM containing
MLC2A mutations. These effects have been recently validated
in vivo after the characterization of a knock-in Glialcam mice
containing the mutation G89S identified in MLC2B patients (9).
This mutation affected the targeting of the protein to cell–cell
junctions in Bergmann glia, showed vacuoles in the cerebellum
in homozygous mice and the heterozygous mice for this muta-
tion showed also a partially altered GlialCAM localization.
All GLIALCAM missense mutations studied to date in the
first IgV domain reduce the ability of the mutant to interact
with GlialCAM WT in the same cell. However, the mutation
p.D128N, identified in MLC2B patients, showed an equal ability to
interact with GlialCAM WT (14). Thus, a reduced interaction with
GlialCAM WT does not sufficiently explain why some mutations
behave in a dominant or in a recessive manner. Furthermore,
none of the GLIALCAM MLC2A or MLC2B mutations identified
to date show a decrease in the interaction of GlialCAM with
MLC1 or ClC-2, and all GlialCAM mutants are still able to change
the functional properties of ClC-2, although its targeting to cell
junctions is abolished (14).
So far, there is no evidence to suggest molecular clues that
could be used to predict the genetic behaviour of GlialCAM
mutants. One puzzling example is that some amino acids have
been found containing recessive (the mutation p.R92Q was iden-
tified in MLC2A patients) or dominant mutations (the mutation
p.R92W was identified in MLC2B patients) (4). Therefore, the
molecular basis explaining why a mutation in GLIALCAM is
recessive or dominant is completely unknown.
In this work, we aimed to understand the biochemical basis
that determines why some GLIALCAM mutations behave as
recessive or as dominant. Using a combination of computational
and biochemical approaches, we provide a model for GlialCAM
homo-interactions that explains the genetic behaviour of
GLIALCAM mutations.
Results
Biochemical characterization of newly identified MLC2B
GLIALCAM mutations
Previous studies (14) characterized most missense GLIALCAM
mutations identified in MLC2A and MLC2B patients located in
the first IgV domain. These studies indicated that nearly all
IgV mutations caused a reduction of the targeting of GlialCAM
to cell–cell junctions as well as a reduced ability to interact
with GlialCAM WT (as measured by split-TEV assays). An excep-
tion was the mutation p.D128N that, despite having a targeting
defect, maintained its ability to interact with WT GlialCAM (14).
We characterized in more detail two newly identified MLC2B
GLIALCAM mutations, p.S59N (2) and p.Q56P (16). Both mutations
showed a targeting defect to cell–cell junctions (Fig. 1A and B).
Then, we analyzed their ability to interact with GlialCAM WT
using split-TEV assays. The experiments showed that mutants
p.Q56P and p.S59N maintained the ability to interact with Glial-
CAM WT, as the mutant p.D128N (14) (Fig. 1C).
Taking these new results into account, we classified
mutations affecting residues into the first IgV domain of
GlialCAM into three different groups (Fig. 1D): 1) mutants found
in MLC2A patients (in green: p.R98C, p.R92Q) that show a reduced
ability to interact with GlialCAM WT; 2) a subset of mutants
(Dominant 1, D1) found in MLC2B patients (in red: p.G89S/D, p.
R92W) with a reduced ability to interact with GlialCAM WT; and
3) a subset of mutants (Dominant 2, D2) found in MLC2B patients
(in blue: p.Q56P, p.S59N, p.D128N) which display a normal ability
to interact with GlialCAM WT. In a homology model of GlialCAM
monomer (see Materials and Methods) (Fig. 1E), D2 mutants
were in predicted loops within the same region of the IgV
domain, very close in space, despite some of them being far
in sequence.
In vitro biochemical assays of the dominant behaviour
of MLC2B mutants
To systematically analyze the dominant behaviour of MLC2B
mutations, we developed a simple test to determine whether a
mutation was acting as dominant in terms of altered trafficking
of the WT protein. To achieve this, we transfected HeLa cells
with pCDNA3 GlialCAM (WT or containing an MLC2 mutation)-
E2A-flag-tagged WT GlialCAM, which allowed the stoichiometric
expression of untagged WT/mutant GlialCAM and flag-tagged
WT (Fig. 1F, inset). We also co-transfected with MLC1 in order
to maximize the cells containing GlialCAM at cell–cell junc-
tions, as previously described (15). We then evaluated the per-
centage of cells where the flag tagged GlialCAM protein was
located at cell–cell junctions by immunofluorescence experi-
ments. These experiments indicated that GlialCAM containing
an MLC2A mutation (p.R92Q) did not influence the localization
at cell–cell junctions of the flag-tagged WT GlialCAM, whereas
GlialCAM containing two different types of MLC2B mutations
(p.R92W and p.D128N) reduced the localization of flag-tagged
GlialCAM at cell–cell junctions (Fig. 1F). Thus, this newly devel-
oped assay was suitable to elucidate whether a GlialCAM mutant
was affecting in a dominant manner, the junctional trafficking
of the WT protein.
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Figure 1. Dominant and recessive MLC2 mutations in GLIALCAM. (A) Subcellular localization of flag-tagged WT or S59N GlialCAM at cell–cell junctions. Scale bar: 20 μm.
(B) Quantification of WT and S59N GlialCAM at cell–cell junctions. ∗∗∗P < 0.001 when compared with the WT in paired t-student test. Graphics represent mean ± SEM.
(C) Split-TEV assays of GlialCAM WT interaction with different GlialCAM dominant mutants Q56P, S59N and D128N. Protein 4F2 is used as a negative control of protein
interaction. Graphics represent mean ± SEM. ns = non significative, ∗P < 0.05 when compared with GlialCAM WT-WT interaction in Bonferroni multiple comparison’s
test of five different experiments. (D) Classification of GlialCAM IgV mutants according to inheritance (dominant or recessive) and the results of a biochemical assay
that measures the level of interaction of the mutants with GlialCAM WT. Mutants are coloured according to this classification. Recessive mutants are coloured in
green, dominant mutants (D1) that show a reduced oligomerization in red, and dominant mutants (D2) with a normal oligomerization in blue. (E) Three-dimensional
homology model of the IgV domain of GlialCAM, with the position of the mutations highlighted. (F) Quantification of the percentage of GlialCAM WT cell–cell junction
targeting when co-expressed with the GlialCAM WT (130 pair of cells counted) recessive mutant p.R92Q (115 pair of cells) dominant p.R92W (128 pair of cells) or
dominant p.D128N (119 pair of cells). Graphics represent mean ± SEM. ns = non-significant, ∗∗P < 0.01 when compared with co-expression with the WT, ## P < 0.01
when comparing dominant mutants with recessive mutant p.R92Q with Bonferroni multiple comparison’s test of four different experiments. The inset is a schematic
representation of the dominance assay performed, where different GlialCAM proteins (WT or mutant) are co-expressed with flag (F)-tagged GlialCAM WT is achieved
by the fusion of both proteins through an E2A peptide.
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Characterization of a newly developed nanobody that
blocks GlialCAM targeting at cell junctions
As indicated in previous studies (9,13), GlialCAM may form
homophilic interactions in cis (within the same cell) and
homophilic interactions in trans (with the neighbouring cell)
in order to localize at cell–cell junctions. With the aim of getting
information about the regions of the GlialCAM molecule that
may be important in mediating trans interactions, we developed
nanobodies recognizing the extracellular side of GlialCAM.
Interestingly, the application of one of the developed nanobodies
(Nb 139G1) to cells expressing GlialCAM-VFP blocked the
localization of GlialCAM at cell–cell junctions in a concentration-
dependent manner (Fig. 2A). In contrast, the application of a
control nanobody detecting an unrelated protein at the maximal
concentration used did not inhibit GlialCAM localization at cell–
cell junctions.
To find which regions of the extracellular domain of GlialCAM
were recognized by the nanobody, we expressed GlialCAM
with deletions in the IgC2 or in the IgV domain and used
flow-cytometry to detect the expressed protein. To normalize
for expressed protein at the plasma membrane, we used
a monoclonal antibody that detects extracellular GlialCAM.
Previous immunofluorescence experiments indicated that both
mutant forms (lacking either IgV or IgC2 domain) are expressed
at the plasma membrane (13). Deleting the IgC2 reduced partially
the binding of the monoclonal and the nanobody (Fig. 2B). In
clear contrast, deletion of the IgV domain abolished completely
the binding of both antibodies, suggesting that both antibodies
mainly bind to the IgV domain (Fig. 2B).
We then tested whether MLC2 GlialCAM mutants affect the
binding of the nanobody using flow cytometry. We monitored
the binding of the monoclonal antibody as a control of surface
expression, which was similar for all our mutants of interest
(Fig. 2C for p.Q56P). Interestingly, we observed differences in the
binding of the nanobody between the different mutations. We
represented the mutants and the effect on nanobody binding
in the model of GlialCAM monomer (Fig. 2E). Some mutants,
such as p.G89D and p.R98C, decreased binding (Fig. 2D and E).
On the other hand, other mutants such as p.R92Q and p.R92W
increased binding (Fig. 2D and E). Importantly, mutant p.Q56P
was the only that showed completely abolished binding of the
nanobody (Fig. 2C–E).
Investigating D2 MLC2B mutants reveal a mechanism
of dominance
From our previous results using a nanobody that blocked Glial-
CAM junctional targeting possibly by inhibiting trans interac-
tions, we hypothesized that the region close to residue Q56
may be involved in the formation of these trans interactions.
Accordingly, we reasoned that mutations p.Q56P, p.S59N and
p.D128N, which are all very close in space and are all D2 dom-
inant mutants, may affect specifically trans interactions. The
replacement of a glutamine by a proline may introduce a kink
in the beta-strand. Nonetheless, how mutations p.S59N and
p.D128N may affect the structure was unclear.
In western blot experiments, we realized that mutants p.S59N
and p.D128N showed a higher motility in SDS gels than the
WT protein (Fig. 3A). Analyzing the amino acid protein sequence
around the mutation, we noticed that in both cases, the muta-
tions putatively introduced new N-glycosylation sites (Fig. 3B).
To prove that this was the case, we compared the motility of
GlialCAM WT and these mutants after treatment with Endo
Glycosidase-F (Endo-F), which removes all N-glycosylation sites
(Fig. 3C). The motility of the mutants in SDS after treatment with
Endo-F was equal to the motility of the WT protein, indicat-
ing that the mutants in fact introduced a new N-glycosylation
site. Thus, we speculate that the new glycosylations created
by these mutations might affect specifically trans interactions
within GlialCAM proteins.
After careful analysis of homologous structures, we iden-
tified a possible template for trans interactions, between the
domains 2 and 3 of contactin (PDB 3JXA) (17). This protein has
the highest sequence identity with the GlialCAM extracellular
domain (30% SI) (Fig. 3D). Therefore, we built a trans dimer by
superimposing two copies of the GlialCAM monomer model on
contactin domains 2 and 3. In this model, the three mutations
studied here mapped to the same interface (Fig. 3E). We therefore
conclude that D2 mutations are dominant because they specif-
ically disrupt trans interactions between opposed molecules,
without interfering with GlialCAM homooligomerization in the
same cell.
Experiments toward the development of a structural
model of GlialCAM dimers
We further aimed to clarify the molecular basis for the domi-
nance of D1 mutants. As happens in other diseases caused by
mutations with both recessive and dominant behaviours (18), we
reasoned that the dominant mutations might affect specifically
protein contact interfaces of the GlialCAM molecule. As previous
studies reported a cis dimer orientation that was quite conserved
in other members of the CAM family (e.g. nectin-1-EC, CAR) (19),
we explored whether GlialCAM could adopt the same cis dimeric
orientation by superimposing two copies of the monomer model
on the corresponding subunits of the CAR dimer.
We first aimed to demonstrate using experimental evidence
that the resulting template-based cis model may be correct. The
model suggested the existence of intermolecular interactions
between the pair of residues D129-R92 and R64-E86 (Fig. 4A).
We performed directed mutagenesis of these residues to change
them to cysteines and expressed in HeLa cells alone or together
with the predicted corresponding pair, and the presence of Glial-
CAM dimers was evaluated by western blot in non-reducing
conditions.
Unexpectedly (Fig. 4B), the mutants E86C and R92C formed
dimers when expressed alone, independently of the co-
expression with the predicted pair. Thus, the cysteine cross-
linking experiments invalidated this first structural model based
on homology modelling.
As the cross-linking experiments suggested that the glu-
tamate 86 (E86) of one GlialCAM monomer was predicted to
be close to the glutamate 86 of the other monomer, we rea-
soned that other closer residues containing a positive charge
might form a positive–negative pair. A closer inspection of the
template-based model showed lysine 68 (K68) of one monomer
in the vicinity of glutamate 86 (E86) of the other monomer
(Fig. 4C), which could be even closer after a small re-arrangement
of the dimeric interface. In agreement with the hypothesis that
E86 is being stabilized by K68, mutating E86 to arginine (p.E86R)
abolished GlialCAM protein expression (Fig. 4D), and its expres-
sion was recovered by mutating additionally K68 to glutamate
(p.K68E) (Fig. 4D). In contrast, expression was not abolished in
the protein containing only the mutation K68E (Fig. 4D) and
both mutants (i.e. p.K68E and p.K68E-E86R) showed a defective
targeting to cell–cell junctions (Supplementary Material, Fig. S1),
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Figure 2. Characterization of a nanobody that blocks GlialCAM localization at cell–cell junctions. (A) HeLa cells were transfected with VFP-tagged GlialCAM WT construct
and treated with different doses of 139G1 Nb (5, 25 and 50 μg); 181 Nb was used as a negative control. Quantification of the percentage of cells with GlialCAM at cell–cell
junctions without Nb was 67.1 ± 2.86% (110 cells), with 5 μg of Nb was 61.7 ± 0.84% (122 cells), 25 μg of Nb was 39.2 ± 4.4% (117 cells), 50 μg of Nb was 27.8 ± 0.5% (111
cells) and 50 μg of Nb control was 68.1 ± 3.4% (104 cells). Graphics represent mean ± SEM. ∗∗ P < 0.01 in ANOVA Bonferroni multiple comparison test against WT. Data
from two independent transfections. (B) Quantification of the percentage of antibody binding in HEK293T cells transfected with GlialCAM WT, IgC2 deletion of GlialCAM
and IgV deletion of GlialCAM using a flow cytometry assay. Deletions of IgV and IgC2 were performed by PCR resulting in the aminoacid sequence ‘..TSPVPISRPQV..’
for del(IgV) and ‘..TTVLQGRSLPV..’ for del(IgC2). Percentage of antibody binding against del (IgC2) and del (IgV) was normalized with the antibody binding against WT.
The mean percentatge of monoclonal antibody (white) against del (IgC2) was 52.8 ± 8.6% (n = 4) and against del (IgV) was 0.42 ± 0.07% (n = 4). The mean percentage of
139G1 Mb (black) against del (IgC2) was 27.46 ± 7.1% (n = 4) and against del (IgV) was 0.74 ± 0.3% (n = 4). Graphics represent mean ± SEM. ∗∗ P < 0.01 ∗∗∗∗P < 0.0001 in
ANOVA Bonferroni multiple comparison test. (C) Representative flow cytometry experiments showing the binding of the monoclonal antibody (left) and the 139G1
monobody (right) in untransfected HEK293T cells and cells transfected with WT and p.Q56P GlialCAM. (D) Quantification of 139G1 Mb binding by flow cytometry assay
in HEK293T cells transfected with different GlialCAM IgV mutants. All the signal of the nanobody for the different GlialCAM IgV mutants were divided by the signal
of the monoclonal antibody and normalized with the 139G1 Mb binding against GlialCAM WT. The mean percentage of antibody binding for each mutant was the
following: p.Q56P was 0.7 ± 0.4% (n = 5); p.S59 N was 47.5 ± 9.9% (n = 5); p.G89D was 22.9 ± 8.1% (n = 4); p.G89S was 43.1 ± 21.4% (n = 4); p.R92Q was 176.3 ± 23.9% (n = 4);
p.R92W was 189.3 ± 26.3% (n = 4); p.R98C was 17.1 ± 4.5% (n = 3) and p.D128N was 42.3 ± 13.8% (n = 5). Graphics represent mean ± SEM. ns = non-significant; ∗P < 0.05;
∗∗P < 0.01 in ANOVA Bonferroni multiple comparison test.
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Figure 3. Dominant mutants p.S59N and p.D128N introduce new glycosylation sites in GlialCAM. (A) Western blot of transfected cells with flag-tagged GlialCAM WT or
carrying dominant or recessive mutations was performed with an antibody detecting the flag epitope. Dominant mutants p.S59N and p.D128N present an increased
molecular weight. Another independent experiment gave the same results. (B) Predicted N-glycosylation motifs that appear in the GlialCAM amino acid sequence due
to the p.D128N or the p.S59N dominant mutations. (C) Western-blot assay of transfected cells with WT, p.S59N or p.D128N GlialCAM plasmids in control conditions (left)
or treated with Endoglycosidase-F (Endo-F) (right) that removes all asparagine-linked mannoses. Treatment with Endo-F results in all GlialCAM constructs presenting
the same molecular weight around 50 kDa. Two additional experiments gave the same results. (D) Alignment between the Ig domains of contactin and GlialCAM. The
IgV domain of GlialCAM is coloured in red and the IgC2 domain in blue. (E) Homology model generated to explain the trans interaction between the IgV domain of two
GlialCAM molecules with key dominant mutants p.Q56P, p.S59N and p.D128N highlighted in blue.
suggesting that E86 may form additional interactions with other
residues.
Development of a new structural model of GlialCAM
dimerization
Since mutational data and cross-linking experiments did not
support the template-based dimer model, we decided to model
the cis dimer by docking, using the monomer model as input (see
Materials and Methods). We selected only docking orientations
in which E86 residues from both molecules were within 8 Å
distance. From the resulting docking models, the one with the
closest E86-K68 distance (6.3 Å) was consistent with all the
above mutational data and cross-linking experiments. The new
model suggested a large interface formed by the surfaces of the
same opposing beta-strands of the IgV domains of two GlialCAM
molecules (Fig. 5A, dotted-rectangle in yellow). The interacting
segment was formed by residues ranging from Glutamate 86
(E86, in the top) to Arginine 92 (R92, in the bottom) of each
GlialCAM molecule (Fig. 5A). To test if this segment (beta strand)
from each GlialCAM monomer was interacting in the dimer, we
generated new cysteine mutants from the residues of this strand
(Isoleucine 88 (I88), Threonine 90 (T90), Leucine 91 (L91)). As a
control, we generated the cysteine mutant of Glutamine 81 (Q81),
which is also very close, but it is not predicted to be interact-
ing. After expressing these mutants in HeLa cells, we analyzed
the formation of GlialCAM dimers by western blot (Fig. 5B). We
observed the dimer formation between the pairs of residues E86,
I88, T90, L91 and R92, but not with Q81. Treating the extracts with
reducing agents (DTT) disrupted the dimers, further confirming
that dimers of the cysteine mutants were formed by disulphide
bonds (Fig. 5B). In summary, these experiments indicated that
the residues from positions 86 to 92 form a specific GlialCAM–
GlialCAM interacting segment.
As an additional test that this segment was interacting, we
reasoned that introducing a glycosylation site in that segment
might work as a dominant mutation. Mutation I88N (Fig. 5C),
which increased the motility of GlialCAM because it introduces
a new glycosylation (Fig. 5C, inset), caused a dramatic reduction
of GlialCAM WT targeting to cell junctions (Fig. 5D). As a control,
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Figure 4. Development and biochemical testing of a structural domain of GlialCAM cis-homooligomerization. (A) Three-dimensional model of GlialCAM generated
by homology modelling using another IgCAM molecule as a template. Possible pairs of interacting residues R64-E86 and R92-D129 are highlighted in orange/purple
colours. (B) Western blot of GlialCAM WT or mutants changed to Cysteine R64C, E86C, D129C and R92C expressed alone or co-transfected in pairs (R64C + E86C and
D129C + R92C) performed to observe Cysteine cross-linked dimerization between the two-paired mutants. Mutants E86C and R92C alone show dimerization, as observed
at the 140 kDa band. Representative western blot from three independent experiments. (C) Structural representation of the negatively charged residue E86 in the IgV
dimer interface. Structural analysis revealed the positively charged residue K68 in the vicinity of E86, which could be even closer after a small interface rearrangement.
(D) Western blot of transiently transfected cells with GlialCAM WT, K68E mutant, E86R mutant or GlialCAM carrying both aminoacid changes K68E and E86R. While
E86R is not expressed, double mutant E86R + K68R protein levels are recovered and similar to protein levels of GlialCAM WT. Data shown are from a representative
experiment, out of three independent ones. Actin was used as a loading control.
mutation P76N (Fig. 5C), which also introduces a glycosylation
site, reduced only slightly the targeting of GlialCAM WT to cell
junctions (Fig. 5D).
Additional characterization of cysteine mutants in the
interacting segment provide new keys to differentiate
dominant and recessive mutants
We additionally assessed if these cysteine mutants from the
GlialCAM interacting segment showed a defect in the targeting to
cell–cell junctions (Fig. 6A). Unexpectedly, compared with Glial-
CAM WT expressed alone, mutant E86C showed an increased
targeting to cell–cell junctions, reaching the same values of the
co-expression of GlialCAM plus MLC1 (Fig. 6A) (15). In contrast, all
the other cysteine mutants (I88C, T90C, R91C and R92C) showed
a defect in the targeting to cell–cell junctions.
Given these results, we reasoned that mutation E86C might
stabilize the GlialCAM dimer in a more stable conformation,
which will result in an increased targeting of the mutant to cell–
cell junctions. Then, we decided to explore whether the intro-
duction of the mutation E86C might reverse the trafficking defect
caused by recessive or dominant mutations. It was found (Fig. 6B)
that the E86C mutation rescued almost completely the traffick-
ing defect caused by the recessive mutation p.R92Q, while it did
not increase the targeting of dominant mutants (D1 (p.R92W)
and D2 (p.S59N)) to cell junctions (Fig. 6B).
Analyzing the structural mechanism of dominance
of some MLC2B mutations
From all GLIALCAM mutations identified in MLC2B patients,
those affecting their interaction with GlialCAM (i.e p.G89S/D,
p.R92W) are found in the identified cis-dimerization interacting
segment. In contrast, all the MLC2A mutations except p.R92Q
are found outside of this segment (p.K68M, p.R98C, p.T132N),
suggesting that mutations located in this specific segment will
be dominant. To understand the behaviour of the residue R92, we
constructed several mutants of this residue to different amino
acids, co-expressed them with GlialCAM WT (Fig. 7A) and ana-
lyzed whether they behave in a dominant or recessive manner
regarding the targeting of GlialCAM WT. Mutation of R92 to the
small amino acid alanine (A) did not result in a significant dom-
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Figure 5. Three-dimensional model of GlialCAM homo-dimerization based on docking. (A) Structural representation of the new structural model of GlialCAM dimer
based on docking analysis after applying several constraints based on the results from biochemical studies. The interacting surface between the two IgV domains is
highlighted in yellow (left). Residues E86 and R92 are paired in close proximity and residue K68 is also highlighted. (B) Western-blot assay of cysteine cross-link in
the absence or in the presence of 100 mm DTT between the following residues mutated to cysteine: Q81C, E86C, I88C, T90C, L91C and R92C. GlialCAM WT is used as a
negative control. Dimers are observed on the mutants E86C, I88C, T90C, L91C and R92C at 140 kDa. Representative western-blot of three independent experiments. (C)
Scheme of the IgV interaction showing the position of the introduction of two different glycosylation sites, I88N in the interacting segment and P76N as a control. The
inset shows a western blot of transfected cells with flag-tagged GlialCAM WT or carrying the introduced glycosylation sites detected with an antibody detecting the
flag epitope. Both P76N and I88N present an increased molecular weight. Another experiment gave the same results. (D) Biochemical dominance assay of GlialCAM
WT targeting to cell–cell junctions co-expressed with different glycosylation mutants. Quantification of flag-tagged GlialCAM at cell–cell junctions (right) when co-
expressed in E2A constructs with GlialCAM WT (232 cells), mutant P76N (174 cells) and mutant I88N (176 cells). Graphics represent mean ± SEM. ∗∗P < 0.01, ∗∗∗P < 0.001
when compared with co-expression with the WT. In addition, we also compared with the mutant P76N, to distinguish better between recessive and dominant effects.
##P < 0.01 when comparing I88N with mutant P76N in Bonferroni multiple comparison’s test of three–four different experiments.
inant effect, whereas mutation to tryptophan (W) or tyrosine (Y)
was dominant (Fig. 7A). Interestingly, mutants R92 to aspartate
(D) or cysteine (C) were also dominant (Fig. 7A). We hypothesized
that the dominant mutants of this residue may have the ability
to form novel interactions around this region, maybe distorting
the native dimer orientation.
By inspecting in the new dimer model residues near to the
position of R92 in the other monomer, we found R96 (Fig. 7B).
To test the putative interaction of R92 mutants with R96, we
focused on the mutant R92D and then constructed the single
mutant R96D and the double mutant R92D/R96D and assayed
its localization at cell–cell junctions (Fig. 7C). Both R92D and
R96D mutants showed a defective targeting to cell–cell junctions
(Fig. 7C). In contrast, the double mutant R92D-R96D was targeted
to cell junctions as the WT protein.
In summary, our results suggest that there is an interac-
tion segment between residues E86 (located on the top of the
beta strand) and R92 (found in the bottom) (Fig. 7D). Although
residues E86 from each dimer are close, they are stabilized by
its interaction with K68. In the bottom edge, opposed residues
Human Molecular Genetics, 2020, Vol. 29, No. 7 1115
Figure 6. Characterization of the trafficking to cell junctions of GlialCAM cysteine mutants in the interacting segment. (A) Percentage at cell–cell junctions of GlialCAM
E86C (230 cells) I88C (177 cells) T90C 185 cells) L91C (123 cells) and R92C (91 cells) compared with GlialCAM WT (198 cells). Graphics represent mean ± SEM. ∗P < 0.05,
∗∗P < 0.01 in Bonferroni multiple comparison test versus WT of three independent experiments. ##P < 0.01 in T-student test compared with WT in data from four
independent experiments. (B) Quantification of percentage of cells with GlialCAM in cell junctions for WT (101 cells) E86C (94 cells), E86C-p.R92Q (356 cells), E86C-
p.R92W (137 cells) and E86C-p.S59N (147 cells). Graphics represent mean ± SEM. ∗∗P < 0.01 and ∗∗∗P < 0.001 in Bonferroni multiple comparison test, compared with WT.
Data from three independent experiments.
R92 may be slightly separated through electrostatic repulsion
with R96 (Fig. 7D). The mutation of R92 by charged aspartate can
introduce favourable salt bridge with R96 of the other monomer,
bringing to a close vicinity this bottom region that in princi-
ple was slightly separated in the native protein. Similarly, the
introduction of aromatic residues (tryptophan or tyrosine) could
introduce novel cation-pi interactions with R96, producing sim-
ilar effect. The dominant effect of R92C might also be explained
by the formation of dipole–dipole interactions or by a disulphide
bridge, suggesting that GlialCAM may form oligomers of dimers
by lateral interactions (see Discussion). Thus, we speculate that
residues in this segment that create aberrant neo-interactions,
which might be inducing a different dimer orientation, may be
dominant.
Discussion
Our aim was to understand why missense mutations from the
first Ig domain (IgV), which are found in MLC2 patients, differen-
tially behave as dominant or recessive. The study of most MLC2B
missense dominant mutations that have a trafficking defect has
revealed that they can be classified in two groups taking into
account regarding whether they display or not a reduced ability
to interact with the WT protein. Locating both types of MLC2B
mutations in a structural model of the extracellular domain of
GlialCAM protein developed in the present work, which takes
into account homologous structures, docking energetics and
biochemical experiments (Fig. 8), suggested that both types of
MLC2B mutations affect GlialCAM-GlialCAM interacting inter-
faces. In one case (D1), they may affect to interactions involved
in GlialCAM–GlialCAM cis interfaces, whereas for the other group
of mutants (D2), they allegedly affect interactions involved in
GlialCAM–GlialCAM trans contacts. As it has been shown in other
IgCAM molecules (20,21), GlialCAM dimers may be formed first
in the endoplasmic reticulum through cis mediated interac-
tions that then will travel to the plasma membrane where trans
interactions may occur. We suggest that MLC2B mutants that
showed normal ability to interact with GlialCAM WT may disrupt
specifically GlialCAM–GlialCAM trans mediated interactions, for
instance as in the case of the mutants p.S59N and p.D128N,
by creating a new glycosylation site in the mentioned trans
interaction surface. Possibly, mutant p.Q56P may also disrupt
this interaction surface, as proline has a restricted degree of
freedom.
Furthermore, GlialCAM is also able to form heterophilic cis
interactions with MLC1 or ClC-2. It has been previously shown
that, although GlialCAM alone reach cell–cell junctions, co-
expression with MLC1 increases the percentage of GlialCAM
present at cell–cell junctions. Here, we have found a mutant,
E86C that also improves the ability of GlialCAM to reach cell–
cell junctions. Based on these studies, we suggest that MLC1
may stabilize GlialCAM at cell–cell junctions by changing the
conformation of GlialCAM to a similar configuration as the one
caused by the mutation E86C.
We analyzed whether mutation E86C could stabilize MLC2A
and MLC2B mutants. As the MLC2B p.S59N mutant was not
rescued by E86C, we suggest that mutants E86C and p.S59N
influence GlialCAM stability by different mechanisms. Contrar-
ily, the double mutant containing E86C and the MLC2A recessive
mutation p.R92Q showed a normal targeting to cell–cell junc-
tions, but the double mutant E86C-R92W failed to reach cell–
cell junctions. We believe that the MLC2B mutant p.R92W may
destabilize cis interactions in a different manner than the MLC2A
mutant p.R92Q, probably by creating novel interactions, as our
experiments with the double mutant R92D-R96D suggest. MLC2B
mutant p.R92W may also form novel cation-pi interactions with
the residue R96. Thus, we conclude that MLC2B mutants affect-
ing GlialCAM homooligomerization may affect the interacting
segment by disrupting extensively the normal pattern of inter-
actions in this segment, as for example, by creating new interac-
tions or by affecting several interactions simultaneously. Using
this model, for instance, we could explain why the recently
identified p.R92P mutation in MLC2B Chinese patients (22) may
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Figure 7. Structural clues on the difference between dominant and recessive mutants at the CIS interacting surface. (A) Biochemical dominance assay of GlialCAM WT
targeting to cell–cell junctions co-expressed with different R92 mutants (left). Quantification of flag-tagged GlialCAM at cell–cell junctions (right) when co-expressed in
E2A constructs with GlialCAM WT (130 cells), mutant p.R92Q (115 cells) R92A (94 cells), R92Y (115 cells), R92D (127 cells), R92C (114 cells) and p.R92W (128 cells). Graphics
represent mean ± SEM. ns = no statistical differences, ∗∗P < 0.01, ∗∗∗P < 0.001 when compared with co-expression with the WT. In addition, we also compared with the
mutant p.R92Q, to distinguish better between recessive and dominant mutations. ns = no statistical differences, ##P < 0.01, ###P < 0.001 when comparing with mutant
R92Q in Bonferroni multiple comparison’s test of three–four different experiments. (B) Structural representation of the interaction between two IgV domains in CIS,
with focus on the possible interactions between the residue R92 and the residue R96. (C) Immunofluorescence of flag-tagged WT and GlialCAM mutants R92D, R96D
or double mutant R92D-R96D, where localization at cell–cell junctions is compared with the WT protein. Quantification of percentage of cell–cell junctions in WT (235
cells), R92D (240 cells), R96D (293 cells) or R92D + R96D (278 cells). Graphics represent mean ± SEM. ∗P < 0.05 and ∗∗P < 0.01, ns = no statistical differences, in Bonferroni
multiple comparison test, compared with WT. Data from three independent experiments. (D) A proposed model of GlialCAM IgV dimerization indicates that dimer is
stabilized both by attracting charges at the top of the IgV interacting segment and by repulsive charges at the bottom.
be also dominant. We also hypothesized that the MLC2B mutants
p.G89S and p.G89D may also form new interactions through new
hydrogen bonds or by electrostatic effects.
As previous studies have revealed (13), efficient targeting of
GlialCAM to cell–cell junctions may require multiple interac-
tions of GlialCAM with GlialCAM forming a GlialCAM dimer in
the same or in the opposite cell, but also with the cytoskele-
ton through the C terminus, and with MLC1 or ClC-2 through
unknown interacting surfaces. Moreover, recent work has shown
that GlialCAM, MLC1 and ClC-2 may form a ternary complex (23).
Considering the volume of the ClC-1 channel (homologous to
ClC-2) (24), in the GlialCAM dimer, there is only space for ClC-
2, but not for MLC1. Thus, we suggest that GlialCAM dimers
may also form lateral interactions with other GlialCAM dimers
accommodating ClC-2 or MLC1 within a dimer. The presence
of multiple GlialCAM dimers could explain how mutation R92C
may be dominant, as the possible formation of a disulphide
bridge in one of these different dimers containing two GlialCAM
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Figure 8. Summary of the structural model proposed for GlialCAM homodimers forming cis and trans interaction through different surfaces of its IgV domain. Cis
dimerization is achieved by interactions between two opposing beta-strands of the IgV domain and trans interactions occurr between salient loops of both IgV domains.
Residues mutated in MLC2A patients (recessive) are shown in green, D1 residues mutated in MLC2B patients are shown in red and D2 residues mutated in MLC2B patients
are shown in blue. The classification of D1 and D2 mutants has been explained previously.
molecules with R92 mutated to cysteine may destabilize the
overall oligomeric organization at the cell junction. It has been
shown that other IgCAM molecules similar to GlialCAM have the
ability to form lateral interactions that are also important for
clustering through IgC2 domains (20). Therefore, maybe some
mutations found in MLC2 patients in the IgC2 domain may affect
GlialCAM–GlialCAM lateral interactions.
To conclude, our structural model (Fig. 8) of GlialCAM–
GlialCAM dimers mediating cis and trans interactions could
be used to predict the behaviour of new MLC2 mutants (22).
For instance, the recently identified MLC2A mutation p.T132N
is not found in an interacting surface of GlialCAM, so it may
be recessive. The other new mutant identified, p.K68M, may
destabilize GlialCAM–GlialCAM interaction by affecting its
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electrostatic interaction with E86. Since it is not creating a new
interaction, we propose it may also be recessive. In summary,
this work provides new insights into the molecular basis of
GLIALCAM mutations. We believe that this knowledge will be
important to help developing therapeutic strategies for MLC
patients with GLIALCAM mutations.
Materials and Methods
Molecular biology
Plasmids were constructed using standard molecular biology
techniques employing recombinant PCR and the Multisite Gate-
way System (Invitrogen, Carlsbad, CA, USA). For localization
studies, all GlialCAM constructs were flag tagged at their C-
terminus (three flag copies) and cloned into the pCDNA3 vector.
Flag tagged WT GlialCAM was co-expressed with different Glial-
CAM mutants by generating constructs where both cDNAs were
linked to the self-cleavable 2A peptide (E2A). The sequence of
the E2A peptide was: Gly-Ser-Gly-Glu-Gly-Arg-Gly-Ser-Leu-Leu-Thr-
Cys-Gly-Asp-Val-Glu-Glu-Asn-Pro-Gly. The integrity of all cloned
constructs was confirmed by sequencing. All cDNAs are from
human origin. In the results section, mutations found in patients
are mentioned using the genetic nomenclature (for instance
p.R92W), whereas other mutants simply describe the mutation
(for instance E86C).
Cell transfection
HeLa cells were grown in Dublecco’s modified Eagle’s medium
containing (v/v) 10% foetal bovine serum (FBS, Sigma, St
Louis, MO, USA) 1% glutamine and 1% penicillin/streptomycin
at 37◦C in a humidity controlled incubator with 5% CO2.
Cells were transiently transfected with Transfectin Lipid
Reagent (Bio-Rad, Madrid, Spain) following the manufacturer’s
instructions (https://www.bio-rad.com/webroot/web/pdf/lsr/
literature/4106254A.pdf). Experiments were performed 48–72 h
after cell transfection. To assay whether a mutant was acting
in a dominant manner, cells were co-transfected with GlialCAM
WT (or mutant)-E2A- GlialCAM WT-flag tagged plus MLC1. This
was done to maximize the percentage of GlialCAM in cell–cell
junctions, as it was previously described that MLC1 improves
the percentage of GlialCAM in cell–cell junctions (15). In this
case, we always detect MLC1 and flag-tagged GlialCAM by
immunofluorescence and performed our quantitative analyses
on GlialCAM only on cells that express MLC1. To study the effect
of mutations on GlialCAM trafficking, GlialCAM WT or mutant
flag-tagged were transfected independently.
Immunofluorescence of transfected cells
Twenty four hour transfected HeLa cells were split and trans-
ferred onto glass coverslips in Petri dishes, and grown for further
24–48 h. Later, cells were fixed with phosphate-buffered saline
(PBS) containing 3% paraformaldehyde (PFA) for 20 min, blocked
and permeabilized with 10% FBS and 0.1% Triton X-100 in PBS for
2 h at room temperature (RT). Primary antibodies were diluted in
the same solution and incubated 1 h at RT. The antibodies used
were mouse anti-flag (1:500) (Sigma) and polyclonal rabbit anti-
MLC1 (1:100) (25). Cells were washed and incubated with sec-
ondary antibodies for 2 h at RT. Coverslips were mounted in Vec-
tashield medium (Vector Laboratories, Burlingam, CA, USA), with
1.5 μg/mL 4′,6-diamidino-2-phenylindole (DAPI, Sigma) and visu-
alized using a DSU spinning disk confocal microscope (Olympus,
Tokyo, Japan). Pairs of immunostained cells were analyzed man-
ually to determine whether or not the staining was present in
junctions, as described previously (13).
Split-TEV method
The Split-TEV assay was performed exactly as described pre-
viously (Lopez-Hernandez et al. 2011b; Capdevila- Nortes et al.
2012; Jeworutzki et al. 2012). Briefly, TEV protease was divided
into two fragments: the TEV-N (residues 1–118) and the TEV-C
(residues 119–242). TEV-N fragment, the TEV protease recogni-
tion site and the chimeric transcription factor GV were fused
to the C-terminus of GlialCAM WT in a pCDNA3 vector con-
taining a cytomegalovirus promoter. In addition, we fused the
TEV-C fragment to the C-terminus of WT or different GlialCAM
mutants. All proteins with the TEV-C fragments were cloned in
a pCDNA6.2/V5-pL Dest, containing the herpes simplex virus
thymidine kinase promoter, to obtain low to moderate levels
of expression. The non-interacting protein 4F2hc was used as a
negative control.
Cysteine crosslinking assays, western-blot and
glycosylation analysis
For western blot studies, lysates were prepared by cell homog-
enization in PBS containing 1% Triton X-100 and protease
inhibitors: 1 mm pepstatin and leupeptin, 1 mm aprotinin and
1 mm PMSF, incubated for 1 h at 4◦C and centrifuged. Proteins in
supernatants were quantified using the BCA Kit (Pierce, Thermo
Scientific, Rockford, IL, USA) and mixed with SDS loading sample
buffer (LSB4X). When processing samples of proteins that may
establish disulphide bonds, samples were prepared with LSB4X
without reducing agents and boiled for 3 min at 50◦C. In order
to confirm the disulphide-bound nature of dimeric proteins,
protein extracts were treated with 100 mm DTT in SDS loading
sample buffer and boiled at 95◦C for 5 min.
Western blot analysis was performed as previously described
(26). Membranes were incubated with primary antibodies: anti-
Flag (1:500) and anti-beta actin (1:5000, Sigma) and secondary
antibodies: HRP-conjugated anti-mouse (1:5000; Jackson).
Evaluation of glycosylation status of GlialCAM protein was
achieved through denaturing glycosylation assays with PNGase
F (New Englan BioLabs, Ipswich, UK). Protein extracts were dena-
tured by heating at 100◦C for 10 min with glycoprotein denatur-
ing buffer and treated with PNGase F enzyme for 1 h at 37◦C.
Finally, treated samples were prepared with LSB4X and analyzed
by western blot.
Obtention of nanobodies and minibodies against
GlialCAM
The sequence of 139G1 Nb was cloned into the vector pHEN2
that included a hexa-histidine tag at the C-terminus. 139G1 Nb
was produced by Hybrigenic Services SAS, Paris, France. Three
rounds of phage display selection were carried out using cells
expressing GlialCAM. Hybrigenics’ synthetic hsd2Ab VHH library
of 3.109 clones was expressed at the surface of M13 phage.
Hybrigenics’ phage display allowed selecting VHHs recognizing
the non-adsorbed antigen in a native form. Selected VHHs were
validated in non-adsorbed Phage ELISA and were then tested in
FACS assay. The 139G1 nanobody plasmid was amplified in the
E. coli WK6 strain (SBRC, Instruct Integrating Biology, Brussel),
as described previously (27). In brief, 3–4 individual colonies
of the 139G1 Nb were randomly picked, and those were pro-
duced as soluble His- and Capture Select C-tagged proteins (MW
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12–15 kDa) in the periplasm of E. coli. Inducible periplasmic
expression of Nb in E. coli WK6 strain produced milligramme
amounts of > 95% pure Nb using immobilized Ni/NTA Agarose
resin (Qiagen, Hilden, Germany) from the periplasmic extract of
a 1-l culture. Purified Nb (2–10 mg ml−1) in 20 mm Tris-Base, NaCl
150 mm, pH 7.4 were frozen in liquid nitrogen and stored at −80◦C
before use.
The VHH 139G1 coding sequence was inserted in pFuse plas-
mid (Hybrigenic Services), which included an Fc fragment of
rabbit IgG2. The production of 139G1 Minibody (Mb) VHH 139G1
fused at their C-terminus to the Fc fragment of rabbit IgG2 was
carried out in HEK 293 T cells. These cells were grown at 37◦C
in an atmosphere of 5% CO2 in DMEM (Sigma-Aldrich, St Louis,
MO, USA) supplemented with 1 mm sodium pyruvate, 2 mm L-
glutamine, 100 U/ml streptomycin, 100 mg/ml penicillin and
5% (v/v) fetal bovine serum. The cells were seeded on 10 cm
culture dishes and transiently transfected with 10 μg of 139G1
Mb using Trasfectin reagent (Bio-Rad, Hercules, CA, USA). At 24 h
after the transient transfection, the media was exchanged for a
serum-free media, and the cell supernatant was collected 1 day
later. The presence of the Mb in this supernatant was confirmed
by western blot using an HRP-conjugated anti-rabbit antibody
(1:5000; Jackson).
Flow cytometry
For flow cytometry, cells were processed as previously described
(26). Cells were transfected with the different GlialCAM IgV
mutants into six-well plates. Forty-eight hours after transfec-
tion, cells were detached using Trypsin-EDTA 1X (Biological
Industries, Kibbutz Beit-Hanemek, Israel) and resuspended in
500 μL of DMEM (Sigma-Aldrich, St Louis, MO, USA) supple-
mented with 1 mm sodium pyruvate, 2 mm L-glutamine, 100 U/ml
streptomycin, 100 mg/ml penicillin and 5% (v/v) fetal bovine
serum. The following antibodies were used: monoclonal anti-
HepaCAM 0.5 mg/ml (1:50; R&D Systems) and the Mb developed
in this work 139G1 Mb 0.015 mg/ml (1:1; Hybrigenic Services).
These antibodies were added separately to each condition and
incubated for 30 min at 4◦C. Cells were washed once in 1 mL
of 0.2% FBS in PBS and resuspended again in 100 mL of cell
culture medium. The secondary antibodies used were: Alexa
fluor 488 anti-mouse and Alexa fluor 488 anti-rabbit (1:20;
Molecular Probes, Inc., Eugene, OR, USA). Secondary antibodies
were added and further incubated for 30 min at 4◦C. Cells were
rinsed once more and resuspended in 1 mL of 0.2% FBS in
PBS. To assess viability, propidium iodide was added to a final
concentration of 1 mg/ml immediately before FACS analysis,
performed with a Cytometre FACS Canto using the following
filter sets: 550 bandpass (GFP) and 620/22 (PI). Untransfected
cells and unstained transfected cells were used to set the
compensation parameters. Data analysis was performed using
DIBA software.
Incubation of cells with the 139G1 nanobody
HeLa cells transiently transfected with VFP-tagged GlialCAM
WT construct were seeded on coverslips (100.000 cells) and
treated with different doses of 139G1 Nb (5, 25 and 50 μg)
for 24 h. Cells were then fixed with PBS containing 4% PFA
for 20 min and blocked with 10% FBS in PBS for 2 h at RT.
Cells were washed three times and coverslips were mounted
in Vectashield medium (Vector Laboratories) with 1.5 μg/ml
DAPI (Sigma). For the image acquisition, we worked with an
Olympus DSU spinning disk confocal microscope. Experiments
were analyzed using ImageJ. Cells incubated with 50 μg with the
control nanobody 181Nb (28) were used as a negative control.
Modelling of GlialCAM monomer
A model of extracellular GlialCAM (containing the IgV and IgC2
domains) was built with HHPred (29) based on CAR structure
(PDB 3JZ7; 24% SI). There are other available templates for the
GlialCAM extracellular domains with 24–30% SI (e.g. 2V5T 24%,
1F97 28%, 3LAF 29%, 3JXA 30%), but none of them yielded bet-
ter models. Modelling of the IgV alone (with templates 4GOS,
2PKD, 1NEU, 4K55, 3R0N), or using other modelling software (e.g.
PSIPRED, genThreader, pDomThreader, pGenThreader, T-coffee),
did not improve the models.
Modelling of GlialCAM cis dimer
Previous studies reported a cis dimer orientation that was quite
conserved in other members of the CAM family (e.g. nectin-1-EC,
CAR) (19). We initially explored whether GlialCAM could adopt
the same cis dimeric orientation by superimposing two copies of
the monomer model on the corresponding subunits of the CAR
dimer (PDB 3JZ7).
However, mutational data and cross-linking experiments did
not support the template-based dimer model, so we also mod-
elled the cis dimer by docking, using the monomer model as
input. We applied the standard pyDock protocol (30,31). We ran
FTDock for exhaustive scanning of protein–protein orientations
and then evaluated the energy of the 10 000 resulting docking
poses with pyDock scoring function. We finally checked all dock-
ing models in search for those that satisfied mutational data.
Modelling of GlialCAM trans dimer
During our analysis of homologous structures, we identified a
possible template for interactions, between the domains 2 and
3 of contactin (PDB 3JXA) (17). This protein has the highest
sequence identity with GlialCAM extracellular domain (30% SI).
Therefore, we built trans dimer by superimposing two copies of
GlialCAM monomer model on contactin domains 2 and 3.
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Supplementary Material is available at HMG online.
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